Summary
EudraCT Number: 2007-003048-31
Sponsor's Protocol Code Number: P070404
National Competent Authority: France - ANSM 
Clinical Trial Type: EEA CTA
Trial Status: Ongoing
Date on which this record was first entered in the EudraCT database: 2007-07-27
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2007-003048-31/FR/

A. Protocol Information
A.1 Member State Concerned: France - ANSM
A.2 EudraCT number: 2007-003048-31
A.3 Full title of the trial: Etude de phase II du sunitinib ( SUTENT®)  pour le traitement de patients atteints de cancer de la prostate hormono-résistant après progression sous docétaxel.
A.3.2 Name or abbreviated title of the trial where available: PROSUT
A.4.1 Sponsor's protocol code number: P070404
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
B.1.3.4	Country: France
B.3.1 and B.3.2	Status of the sponsor: Non-Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: SUTENT
D.2.1.1.2 Name of the Marketing Authorisation holder: PFIZER
D.2.1.2 Country which granted the Marketing Authorisation: France
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: SUTENT
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: sunitinib 
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 12,5 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: SUTENT
D.2.1.1.2 Name of the Marketing Authorisation holder: PFIZER
D.2.1.2 Country which granted the Marketing Authorisation: France
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: SUTENT
D.3.4 Pharmaceutical form: Capsule, hard
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Oral use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: sunitinib
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 25 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: -Patients présentant un cancer de la prostate métastatique hormono-résistant en progression après une 1ère ligne de traitement par docétaxel.
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 8.1
E.1.2 Level: PT
E.1.2 Classification code: 10062904
E.1.2 Term: Cancer de la prostate
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: Evaluer l'efficacité du SUTENT (sunitinib)  chez les patients atteints d'un cancer de la prostate métastatique hormono-résistant après progression sous docétaxel.
E.2.2 Secondary objectives of the trial: - Tolérance
- Etude du SUTENT et de ses métabolites
- Etude du SUTENT sur les marqueurs biologiques





E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: - Patient âgé de plus de 18 ans
- Patient présentant un adénocarcinome de la prostate diagnostiqué histologiquement, hormono-résistant, et en situation métastatique
- Patients ayant bénéficié d'une première ligne de traitement par docétaxel (seul ou en association avec l'estramustine) et avoir une progression documentée 
- Patients orchidectomisés et/ou traités antérieurement par un agoniste de la LH-RH avec ou sans anti-androgènes, avec ou sans échappement aux anti-androgènes, avec ou sans monothérapie par estramustine, ou par d'autres agents hormonaux. 
- Chimiothérapie par docétaxel et/ou radiothérapie externe interrompue dans les 4 semaines précèdant l'inclusion
- Espérance de vie > 3 mois
- Indice de Performance statut (ECOG) inférieur ou égal à 2
- Fonctions hématologiques, rénales et hépatiques telles que définies ci-dessous :
Polynucléaires neutrophiles sup et égal à1.5 x 109/l 
Plaquettes sup et égal à 100 x 109/l 
Hémoglobine sup et égal à 9 g/dl ; INR   inf ou égal à 1.7
Clairance de la créatinine sup et égal à 50 ml /min 
Albumine sérique sup ou égal à  2.8 g/dl
Bilirubine totale  inf ou égal à 2 x N 
Transaminases inf ou égal à  2.5 x N et  inf ou égal à  5 x N si métastases osseuses ou hépatiques 
Phosphatases alcalines inf ou égal à 2.5 x N et 5 x N si métastases osseuses ou hépatiques 
- Consentement éclairé signé avant la participation à l'étude
- Affiliation à un régime de protection sociale 

E.4 Principal exclusion criteria: - Traitement antérieur avec un anti-angiogénique (SUTENT  ou autre : sorafenib, bevacizumab, etc…)
- Patient ayant reçu plus d'une ligne de chimiothérapie antérieure
- Irradiation antérieure sup à 50% de la moelle osseuse
- Hypertension sévère traitée non contrôlée (systolique > 150 ; diastolique > 90)
- Pathologie cardiovasculaire significative dans le 12 mois précédant le début du traitement : 
Angine de poitrine instable,  infarctus du myocarde, insuffisance cardiaque congestive, greffe de déviation d'artère coronaire, accidents thrombo-emboliques, arythmie cardiaque de grade sup ou égal à 2, fibrillation auriculaire de tout grade
- Traitement par anti-convulsifs et traitement par anticoagulants dérivés de la coumarine en cours ou dans les 2 semaines précédant la première administration de sunitinib. De faibles doses de warfarine (jusqu'à 2 mg/jour) en prophylaxie et les héparines de bas poids moléculaire sont autorisées.
- Antécédents de troubles gastro-intestinaux susceptibles d'interférer avec l'absorption du sunitinib
- Lésions cérébrales ou leptoméningées connues, méningite carcinomateuse, ou compression de la moelle
- Diagnostic d'un deuxième cancer primitif depuis moins de 3 ans, sauf carcinome basocellulaire et cancer de la vessie pT1a sans signe de récidive dans les 12 mois
- Pathologie associée non cancéreuse susceptible d'interférer avec le bon déroulement de l'étude
- Participation à un autre essai clinique dans les 4 semaines précédant l'inclusion

E.5 End points
E.5.1 Primary end point(s): Objectif primaire: efficacité
Evaluation de la survie sans progression , de la mesure du PSA, de la réponse radiologique (critères RECIST), du bénéfice clinique et de la survie globale

Objectifs secondaires
- Tolérance : Evaluation de l' incidence des évènements indésirables significatifs et des évènements indésirables graves

E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: No
E.6.2 Prophylaxis: No
E.6.3 Therapy: Yes
E.6.4 Safety: No
E.6.5 Efficacy: No
E.6.6 Pharmacokinetic: No
E.6.7 Pharmacodynamic: No
E.6.8 Bioequivalence: No
E.6.9 Dose response: No
E.6.10 Pharmacogenetic: No
E.6.11 Pharmacogenomic: No
E.6.12 Pharmacoeconomic: No
E.6.13 Others: No
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: No
E.7.1.2 Bioequivalence study: No
E.7.1.3 Other: No
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): Yes
E.7.3 Therapeutic confirmatory (Phase III): No
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: No
E.8.1.1 Randomised: Information not present in EudraCT
E.8.1.2 Open: Information not present in EudraCT
E.8.1.3 Single blind: Information not present in EudraCT
E.8.1.4 Double blind: Information not present in EudraCT
E.8.1.5 Parallel group: Information not present in EudraCT
E.8.1.6 Cross over: Information not present in EudraCT
E.8.1.7 Other: Information not present in EudraCT
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Information not present in EudraCT
E.8.2.2 Placebo: Information not present in EudraCT
E.8.2.3 Other: Information not present in EudraCT
E.8.3 The trial involves single site in the Member State concerned: No
E.8.4 The trial involves multiple sites in the Member State concerned: Yes
E.8.4.1 Number of sites anticipated in Member State concerned: 12
E.8.5 The trial involves multiple Member States: No
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 3
E.8.9.1 In the Member State concerned months: 0
E.8.9.1 In the Member State concerned days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: No
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): No
F.1.1.3 Newborns (0-27 days): No
F.1.1.4 Infants and toddlers (28 days-23 months): No
F.1.1.5 Children (2-11years): No
F.1.1.6 Adolescents (12-17 years): No
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): Yes
F.2 Gender
F.2.1 Female: No
F.2.2 Male: Yes
F.3 Group of trial subjects
F.3.1 Healthy volunteers: No
F.3.2 Patients: Yes
F.3.3 Specific vulnerable populations: No
F.3.3.1 Women of childbearing potential not using contraception : Information not present in EudraCT
F.3.3.2 Women of child-bearing potential using contraception: Information not present in EudraCT
F.3.3.3 Pregnant women: Information not present in EudraCT
F.3.3.4 Nursing women: Information not present in EudraCT
F.3.3.5 Emergency situation: Information not present in EudraCT
F.3.3.6 Subjects incapable of giving consent personally: Information not present in EudraCT
F.3.3.7 Others: Information not present in EudraCT
F.4 Planned number of subjects to be included
F.4.1 In the member state: 50
F.4.2 For a multinational trial

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2007-08-29
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2007-10-10

P. End of Trial
P. End of Trial Status: Ongoing

